GO:0042799 histone H4K20 methyltransferase activity

Histone H4 lysine 20 (H4K20) methylation is a conserved chromatin modification catalyzed by a specialized class of histone methyltransferases. The Gene Ontology term GO:0042799, histone H4K20 methyltransferase activity, defines the catalytic reaction that transfers a methyl group from S-adenosyl-L-methionine to histone H4 at lysine 20, yielding S-adenosyl-L-homocysteine and methylated H4K20. This activity produces three distinct methylation states, H4K20me1, H4K20me2, and H4K20me3, which are distributed across the genome and associated with different chromatin contexts. High-resolution profiling in human cells has shown that H4K20 methylation patterns are non-random and correlate with functional genomic regions, making this modification a key node in epigenetic regulation. Researchers study GO:0042799 because it connects enzymatic chromatin modification to fundamental processes such as DNA replication, DNA damage repair, cell cycle progression, and gene silencing. The major human enzymes annotated with this activity include SETD8 (also known as KMT5A or SET8), which catalyzes H4K20 monomethylation, and SUV4-20H1 (KMT5B) and SUV4-20H2 (KMT5C), which catalyze di- and trimethylation. Loss-of-function studies in Xenopus have demonstrated that SUV4-20H1/KMT5B is required for multiciliated cell differentiation, linking H4K20 methylation to developmental programs. In cancer, KMT5C drives liver cancer progression and influences therapeutic response to PARP inhibitors, while H4K20me3-mediated repression of inflammatory genes marks a targetable vulnerability in persister cancer cells. Decreased H4K20 trimethylation has also been observed in murine models of heart disease, indicating a role beyond oncology. From a methods perspective, GO:0042799 is interrogated using a combination of chromatin profiling, structural biology, and genetic perturbation. Structural analysis of SET8 bound to nucleosomes has revealed how the enzyme engages its substrate to achieve H4K20-specific methylation. Biochemical reconstitution has shown that H4K20 monomethylation can enable subsequent methylation by PRMT1 in vitro, suggesting crosstalk between different methyltransferases. Viral infection studies have further shown that the H4K20 monomethyltransferase SETD8 promotes global accessibility of herpes simplex virus genomes, highlighting a role in host-pathogen chromatin dynamics. Together, these findings make GO:0042799 a compelling target for both mechanistic discovery and therapeutic development.

GO:0042799, histone H4K20 methyltransferase activity, is a molecular function defined as the catalysis of the reaction: S-adenosyl-L-methionine + histone H4 L-lysine (position 20) = S-adenosyl-L-homocysteine + histone H4 N6-methyl-L-lysine (position 20). In simpler terms, it is the enzyme activity that adds a methyl group specifically to the lysine residue at position 20 of histone H4. This activity can occur in successive steps to generate mono-, di-, and trimethylated H4K20, and it is carried out by SET-domain-containing methyltransferases such as SETD8, SUV4-20H1, and SUV4-20H2.

GO:0042799 is important because H4K20 methylation is a central epigenetic mark that influences chromatin architecture and genome stability. The three methylation states generated by this activity have distinct genomic distributions and functional consequences, and their balance is critical for normal cell physiology. Perturbations in H4K20 methyltransferases have been linked to cancer progression, therapeutic resistance, heart disease, and viral infection, making this activity a high-value target for both basic research and drug discovery. Understanding the enzymes, mechanisms, and regulatory inputs of GO:0042799 can reveal new biomarkers and therapeutic strategies across multiple disease areas.

The following genes encode enzymes or associated factors that carry out or regulate histone H4K20 methyltransferase activity (GO:0042799).

The activity of H4K20 methyltransferases is regulated at multiple levels. Cell cycle progression influences SETD8 activity, with H4K20me1 peaking during S phase and mitosis. DNA damage signals can recruit SUV4-20H enzymes to sites of damage, where H4K20me2 serves as a docking site for 53BP1. In cancer, KMT5C expression is linked to PARP inhibitor sensitivity, suggesting that DNA repair pathways modulate its function. Viral infection can alter SETD8 activity to promote accessibility of viral genomes. Additionally, crosstalk with other histone modifications, such as H4K20me1 priming PRMT1-mediated methylation, provides another layer of regulation.

Dysregulation of H4K20 methyltransferases is increasingly recognized in cancer. KMT5C (SUV4-20H2) drives liver cancer progression and directs therapeutic response to PARP inhibitors, indicating that H4K20 methylation status can influence treatment outcomes. In persister cancer cells, H4K20me3-mediated repression of inflammatory genes is a characteristic feature and a targetable vulnerability, suggesting that this epigenetic mark contributes to drug tolerance. These findings position H4K20 methyltransferases as potential therapeutic targets in oncology.

Decreased H4K20 trimethylation has been observed in murine models of heart disease, linking this chromatin modification to cardiac pathology. Although the mechanistic details remain under investigation, the association suggests that H4K20 methylation may play a role in maintaining cardiac gene expression programs and that its loss could contribute to disease progression.

The H4K20 monomethyltransferase SETD8 promotes global accessibility of infecting herpes simplex virus genomes, indicating that the host enzyme can be co-opted to facilitate viral gene expression. This highlights a role for H4K20 methylation in host-pathogen interactions and suggests that modulating this activity could affect viral replication.

SUV4-20H1/KMT5B is required for multiciliated cell differentiation in Xenopus, demonstrating that H4K20 methylation is essential for specific developmental programs. This finding connects the enzymatic activity to tissue morphogenesis and cell fate decisions, expanding its relevance beyond cancer and disease.

ChIP-seq using antibodies specific for H4K20me1, H4K20me2, and H4K20me3 allows genome-wide mapping of these marks. High-resolution profiling in human cells has revealed distinct distributions of each methylation state, providing a foundation for understanding their functional roles. This method is essential for linking GO:0042799 activity to specific genomic regions and for comparing normal and disease states.

Structural studies of SET8 bound to nucleosomes have elucidated the molecular basis of H4K20 recognition and catalysis. In vitro methylation assays using recombinant enzymes and nucleosomes can measure catalytic activity and substrate specificity, and have been used to demonstrate crosstalk between H4K20me1 and PRMT1. These approaches provide mechanistic insights into GO:0042799.

Knockout, point-mutation, knock-in, and overexpression models generated by CRISPR enable causal testing of H4K20 methyltransferase function. For example, KMT5C knockout has been used to study liver cancer progression and PARP inhibitor response, while SETD8 perturbation has been used to examine viral genome accessibility. These models are critical for linking the enzymatic activity to phenotypes.

RNA-seq and proteomics can reveal downstream effects of altered H4K20 methylation. In persister cancer cells, H4K20me3-mediated repression of inflammatory genes was identified using transcriptomic approaches. Similarly, changes in gene expression upon KMT5C knockout can be profiled to understand how the mark influences cellular programs.

Researchers studying histone H4K20 methyltransferase activity-related genes often need to determine whether a candidate gene is causally involved in a specific phenotype, such as cancer progression, developmental differentiation, or viral infection. EDITGENE provides a comprehensive suite of CRISPR-based services to generate precisely engineered cell models that enable such causal inferences.

GO:0042799, histone H4K20 methyltransferase activity, is a fundamental chromatin-modifying function with broad implications for development, cancer, heart disease, and viral infection. The enzymes SETD8, SUV4-20H1, and SUV4-20H2 generate distinct methylation states that regulate genome stability and gene expression. Continued research using CRISPR models, structural biology, and multi-omics approaches will further illuminate how this activity contributes to health and disease, and may reveal new therapeutic opportunities.